Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: kha vu who wrote (75455)	12/15/1999 6:47:00 PM
From: kendall harmon	Read Replies (1) \| Respond to of 120523

ISIP--excerpt from Dow Jones story <<"This is clearly a setback for Isis" because the study was at an advanced stage, said Oscar Gruss & Son analyst Akhtar Samad, who doesn't have coverage on the company. Company officials weren't immediately available for comment. Because some symptoms of Crohn's, an inflammatory bowel disease, resemble other ailments, it is difficult to pinpoint the number of people affected; but some estimates run as high as 2 million. Samad said that in addition to Crohn's disease, Isis' antisense inhibitor could have been used to treat other inflammatory diseases, addressing a potential market he put at $100 to $200 million. Isis' shares recently slumped 65.5%, or 10 5/32, to 5 11/16, bypassing the 52-week low set March 31. However, the negative news is by no means the end of the story for antisense therapeutics, experts said. "We don't think this is a final nail in the coffin for antisense therapeutics," Samad said. Encouraging data from pre-clinical studies conducted by other drug companies indicate that the antisense treatment may prove to be "a viable platform," he said. Isis's antisense therapy involves synthetically designed DNA chains that block the production of disease-causing proteins. The company's Vitravene drug, an antisense therapy used to treat a rare eye disease found in some AIDS patients, was approved in August 1998.>>